Update on polycystic ovary syndrome

Women's Health

Volumn 2, Issue 4, 2006, Pages 561-569

  Diamanti Kandarakis, Evanthia ^a   Panidis, Dimitrios ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIANDROGEN; BIGUANIDE DERIVATIVE; CLOMIFENE; CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; NANDROLONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ANOVULATION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE INFERTILITY; GENETIC ANALYSIS; GLUCOSE INTOLERANCE; GYNECOLOGIC DISEASE; HIRSUTISM; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LOW DRUG DOSE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PREVALENCE;

EID: 33745609219     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.4.561     Document Type: Conference Paper

References (65)

1. Laven JS, Imani B, Eijkemans MJ, Fauser BC: New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet. Gynecol. Surv. 57, 755-767 (2002).
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT et al.: A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84(11), 4006-4011 (1999).
3. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41-47 (2004).
4. Gambineri A, Pelusi C, Vicennati, Pagotto U, Pasquali R: Obesity and the polycystic ovary syndrome. Int. J. Obes. Relat. Metab. Disord. 26, 883-896 (2002).
5. Apridonidze T, Essah P, Iourno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with PCOS. J. Clin. Endocrinol. Metab. 90, 1929-1935 (2005).
6. Ehrmann D, Barnes R, Rosenfield R, Cavaghan M, Imperial J: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22, 141-146 (1999).
7. Arslanian SA, Lewy VD, Danadian K: Glucose intolerance in obese adolescents with polycystic ovary syndrome: Roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J. Clin. Endocrinol. Metab. 86(1), 66-71 (2001)
8. Tsilchorozidou T, Overton C, Conway GS: The pathophysiology of polycystic ovary syndrome. Clin. Endocrinol. 60, 1-17 (2004).
9. Zhang L-H, Rodriguez H, Ohno S, Miller WL: Serine phosphorylation of human P450c17 increases 17,20-lyase activity: Implications for adrenarche and the polycystic ovary syndrome. Proc. Natl Acad. Sci. USA 92, 10619-10623 (1995).
10. Sam S, Dunaif A: PolySystic ovary syndrome: syndrome XX? Trends Endocrinol. Metab. 14, 365-370 (2003).
11. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41, 1257-1266 (1992).
12. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E: Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am. J. Physiol. Endocrinol. Metab. 281, E392-E399 (2001).
13. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 27(1), 73-100 (2006).
14. Silfen ME, Manibo AM, Ferin M, McMahon DJ, Levine I.S, Oberfield SE: Elevated free IGF-I levels in prepubertal hispanic girls with premature adrenarche: Relationship with hyperandrogenism and insulin sensitivity. J. Clin. Endocrinol. Metab. 87, 398-403 (2002).
15. Sopher AB, Thornton JC, Silfen ME et al.: Prepubertal girls with premature adrenarche have greater bone mineral content and density than controls. J. Clin. Endocrinol. Metab. 86, 5269-5272 (2001).
16. Ibanez L, Ong K, de Zegher F, Marcos MV, del Rio L, Dunger DB: Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinemia and androgenemia from prepuberty to postmenarche. Clin. Endocrinol. 58, 372-379 (2002).
17. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL: The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr. Rev. 26, 251-282 (2005).
18. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millan JL: The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 90(12), 6364-6369 (2005).
19. Adams JM, Taylor AE, Crowley WF Jr, Hall JE: Polycystic ovarian morphology with regular ovulatory cycles: Insights into the pathophysiology of polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 89, 4343-4350 (2004)
20. Yildiz BO, Woods KS, Stanczyk F, Bartolucci A, Azziz R: Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89, 5558-5562 (2004).
21. Robinson S, Rodin DA, Deacon A, Wheeler MJ, Clayton RN: Which hormone tests for the diagnosis of polycystic ovary syndrome? Br. J. Obstet. Gynaecol. 99, 232-238 (1992).
22. Balen AH, Laven JSE, Tan SL, Dewailly D: Ultrasound assessment of the polycystic ovary: International consensus definitions. Hum. Reprod. Update 9, 505-514 (2003).
23. Jonard S, Robert Y, Dewailly D: Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries. Hum. Reprod. (2005) (In press).
24. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D: Ultrasound examination of polycystic ovaries: Is it worth counting the follicies? Hum. Reprod. 18, 598-603 (2003).
25. Pasquali R, Casimirri F: The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin. Endocrinol. (Oxf.) 39, 1-16 (1993).
26. Wang JX, Davies MJ, Norman RJ: Obesity increases the risk of spontaneous abortion during infertility treatment. Obes. Res. 10, 551-554 (2002).
27. Hughesdon PE: Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called 'hyperthecosis'. Obstet. Gynecol. Surv. 37, 59-77 (1982).
28. Webber LJ, Stubbs S, Stark J et al.: Formation and early development of follicles in the polycystic ovary. Lancet 362, 1017-1021 (2003).
29. Stubbs SA, Hardy K, Da Silva-Buttkus P et al.: Anti-mullerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J. Clin. Endocrinol. Metab. 90, 5536-5543 (2005).
30. Schouten LJ, Goldbohm RA, van den Brandt PA: Anthropometry, physical activity and endometrial cancer risk: Results from the Netherlands Cohort Study. J. Natl Cancer Inst. 96, 1635-1638 (2004).
31. Clark TJ, Mann CH, Shah N et al.: Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: A systematic quantitative review. Br. J. Obstet. Gynecol. 109, 313-321 (2002).
32. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L: Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52, 908-915 (2003).
33. Legro RS, Kunselman AR, Dunaif A: Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med. 111, 607-613 (2001).
34. Macut D, Micic D, Cvijovic G et al.: Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J. Pediatr. Endocrinol. Metab. 14(Suppl. 5), 1353-1359 (2001).
35. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB: Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study. Gut 54, 533-539 (2005).
36. Yeh HC, Futterweit W, Thornton JC: Polycystic ovarian disease: US features in 104 patients. Radiology 163, 111-116 (1987)
37. Marchesini G, Brizi M, Morselli-Labate AM et al.: Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450-455 (1999).
38. Carmina E, Longo RA, Rini GB, Lobo RA: Phenotypic variation in hyperandrogenic women influences the finding of abnormal metabolic and cardiovascular risk parameters. J. Clin. Endocrinol. Metab. 90, 2545-2549 (2005).
39. Lord J, Wilkin T: Polycystic ovary syndromT and fat distribution: the central issue? Hum. Fertil. (Camb.) 5, 67-71 (2002).
40. Kaltsas GA, Isidori AM, Besser GM, Grossman AB: Secondary forms of polycystic ovary syndrome. Trends Endocrinol. Metab. 15(5), 204-210 (2004).
41. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A: Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet. Gynecol. Scand. 71, 599-604 (1992).
42. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN: Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome (PCOS). J. Clin. Endocrinol. Metab. 91 (1), 48-53 (2005).
43. Diamanti-Kandarakis E, Piperi C, Piperi C, Kalofoutis A, Creatsas G: Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 62(1), 37-43 (2005).
44. Legro RS: Polycystic ovary syndrome and cardiovaAcular disease: a premature association? Endocr. Rev. 24, 302-312 (2003).
45. DeUgarte CM, Bartolucci AA, Azziz R: Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril. 83(5), 1454-1460 (2005).
46. Legro RS, Finegood D, Dunaif A: A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83(8), 2694-2698 (1998).
47. Mastorakos G, Koliopoulos K, Creatsas G: Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil. Steril. 77, 919-927 (2002).
48. Diamanti-Kandarakis E, Alexandraki K, Protogerou A et al.: Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur. J. Endocrinol. 152(5), 749-756 (2005).
49. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I: Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol. Metab. 86(10), 4666-4673 (2001).
50. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur. J. Endocrinol. 138(3), 269-274 (1998).
51. Diamanti-Kandarakis E, Paterakis T, Alexandraki K et al.: Indices of low grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum. Reprod. 21(6), 1426-1431 (2006).
52. Homburg R, Lambalk CB: Polycystic ovary syndrome in adolescence - a therapeutic conundrum. Hum. Reprod. 19, 1-4 (2004).
53. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med. 338(26), 1876-1880 (1998).
54. Kelestimur F, Everest H, Ünlühizarci K et al.: A comparison between spironolactone plus finasteride and spironolactone in the treatment of hirsutism. Eur. J. Endocrinol. 150, 351-354 (2004).
55. Kelestimur F, Sabin Y: Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil. Steril. 69(1), 66-69 (1998).
56. Nader S, Riad-Gabriel MG, Saad MF: The effect of desogestrel-containing oral contraceptives on glucose tolerance and leptin concentrations in hyperandrogenic women. J. Clin. Endocrinol. Metab. 82, 3074-3077 (1997).
57. Burkman RT Jr: The role of oral contraceptives in the treatment of hyperandrogenism disorders. Am. J. Med. 98(Suppl. 1A), S130-S136 (1995).
58. Azziz R, Gay F: The treatment of hyperandrogenism with oral contraceptives. Semin. Reprod. Endocrinol. 7, 246-254 (1989).
59. Chang RJ, Abraham GE: Effect of dexamethasone and clomiphene citrate on peripheral steroid levels and ovarian function in a hirsute amenorrheic patient. Fertil. Steril. 27, 640-646 (1976).
60. White DM, Poison DW, Kiddy D et al.: Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: An analysis of 109 pregnancies in 225 women. J. Clin. Endocrinol. Metab. 81, 3821-3824 (1996).
61. Farquhar C, Lilford RJ, Marjoribanks J, Vandekerckhove P: Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst. Rev. 20(3), CD001122 (2005).
62. Palomba S, Falbo A, Russo T, Zullo F: Ovulation induction in anovulatory patients with polycystic ovarian syndrome. Curr. Drug Ther. 1, 1-7 (2006).
63. Amer SA, Banu Z, Li TC, Cooke ID: Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: Endocrine and ultrasonographic outcomes. Hum. Reprod. 17, 2851-2857 (2002).
64. Duleba AJ, Banaszweska B, Spaczynski RZ, Pawelczyk L: Simvastatin improves biochemical parameters of polycystic ovary syndrome: Results of a prospective randomized trial. Fertil. Steril. 85(4), 996-1001 (2006).
65. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L: Success of laparoscopic ovarian wedge resection is related to obesity, lipid profile, and insulin levels. Fertil. Steril. 79, 1008-1014 (2003).